View the latest Alnylam Pharmaceuticals Inc. (ALNY) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Business Description. Date Description View/Download; There are currently no reports available that match your selection. Alnylam Pharmaceuticals, Inc. ALNY 125.39 0.52 (0.41%). The deal was earlier reported by The Wall Street Journal.
The one-year ALNY stock forecast points to a potential upside of 11.83. If you’re having trouble finding something specific please send an inquiry to investors@alnylam.com: Mar 24, 2020 The average equity rating for ALNY stock is currently 2.00, trading closer to a bullish pattern in the stock market. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. Get the latest Alnylam Pharmaceuticals, Inc. (ALNY) stock news and headlines to help you in your trading and investing decisions. Alnylam Pharmaceuticals is a leader in the study of RNA interference and is attempting to harness this mechanism to create a new class of drugs. NASDAQ Updated Jun 12, 2020 9:05 PM Shares of Alnylam Pharmaceuticals Inc. ALNY, +4.48% rallied 7.4% in premarket trading Monday, after Blackstone Group Inc. BX, +4.68% confirmed that it was investing $2 billion in the biopharmaceutical company. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Try using different or fewer filters. Learn about Alnylam's pipeline of investigational RNAi therapeutics and how the company is leading the translation of RNAi into a new class of innovative medicines to treat a variety of conditions. Alnylam Pharmaceuticals Inc. company facts, information and stock details by MarketWatch. View alny business summary and other industry information. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its earnings results on Wednesday, May, 6th. Alnylam Pharmaceuticals Stock Forecast: RNAi is broadly considered one of the most promising and briskly advancing areas in biology and drug development today.It offers a potent, clinically corroborated approach for the treatment of a wide range of incapacitating diseases … Find the latest SEC Filings data for Alnylam Pharmaceuticals, Inc. Common Stock (ALNY) at Nasdaq.com. The biopharmaceutical company reported ($1.62) earnings per share for the quarter, topping analysts' consensus estimates of ($1.89) by $0.27. Alnylam Pharmaceuticals Inc. shares reached a high of $138.2599 and dropped to a low of $132.88 until finishing in the latest session at $136.67. ALNY: Get the latest Alnylam Pharmaceuticals stock price and detailed information including ALNY news, historical charts and realtime prices.